

**Department of Planning and Budget**  
**2025 General Assembly Session**  
**State Fiscal Impact Statement**

---

**PUBLISHED: 2/17/2025 12:18 PM**

**ORIGINAL**

**Bill Number:** HB1582 S1

**Patron:** Wachsmann

**Bill Title:** Pharmacists; collaborative agreements; drug therapy.

**Bill Summary:** Specifies that collaborative agreements between pharmacists and other health care providers may include the prescribing, modification, continuation, or discontinuation of drug therapy, provided that the actions take place following diagnosis by a licensed physician, podiatrist, advanced practice registered nurse, registered nurse, or physician assistant. The Senate substitute provides that a pharmacist may prescribe, modify, continue, or discontinue Schedule II through VI controlled substances under a collaborative practice agreement as long as they submit proof of the signed collaborative practice agreement to the Board of Pharmacy and obtain authorization from the Board for such activity.

**Budget Amendment Necessary:** No

**Items Impacted:** n/a

**Explanation:** Any fiscal impacts are minimal and can be absorbed with existing resources. This bill does not require that language updates be made to the proposed Appropriation Act.

**Fiscal Summary:** Any fiscal impacts resulting from this bill are minimal, and it is expected that they can be absorbed with existing resources.

**Fiscal Analysis:** This bill adds language to clarify the specific actions being taken by pharmacists under collaborative agreements with other healthcare providers. While the Boards of Medicine and Pharmacy jointly promulgate regulations that facilitate the development and implementation of such agreements, it is not expected that clarifying the actions available to pharmacists will increase the costs associated with this responsibility.

The most recent substitute for the bill also requires the Board of Pharmacy to validate signed collaborative practice agreements submitted by pharmacists seeking to prescribe, modify, continue, or discontinue a Schedule II through VI controlled substance under such an agreement, and provide authorization for the pharmacist to commence such activity. It is expected that any minor increases to workload or costs associated with such responsibilities can be absorbed with existing resources.

**Other:** n/a